About Fina Biosolutions
Fina Biosolutions is a company based in Rockville (United States) founded in 2006. Fina Biosolutions has raised $3 million across 4 funding rounds from investors including NIH, HHS and SK bioscience. Fina Biosolutions offers products and services including CRM 197, Functionalized Dextrans, and Conjugation Services. Fina Biosolutions operates in a competitive market with competitors including Proteros, Neovacs, Nabla, Biomatter and VERAXA, among others.
- Headquarter Rockville, United States
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Fina Biosolutions, Llc
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$3 M (USD)
in 4 rounds
-
Latest Funding Round
$3 M (USD), Seed
Oct 08, 2024
-
Investors
NIH
& 2 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Fina Biosolutions
Fina Biosolutions offers a comprehensive portfolio of products and services, including CRM 197, Functionalized Dextrans, and Conjugation Services.
Protein used as carrier for conjugate vaccines in preclinical and clinical applications.
Dextrans for polysaccharide conjugation and characterization in biotech services.
Services for vaccine conjugation and training programs.
Funding Insights of Fina Biosolutions
Fina Biosolutions has successfully raised a total of $3M across 4 strategic funding rounds. The most recent funding activity was a Seed round of $3 million completed in October 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Fina Biosolutions
Fina Biosolutions has secured backing from 3 investors, including institutional investors. Prominent investors backing the company include NIH, HHS and SK bioscience.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Innovative vaccines are developed and manufactured by SK bioscience.
|
Locked | Locked | Locked | |
|
Drug discovery services are provided to the biopharma sector.
|
Locked | Locked | Locked | |
|
Public health and human services are overseen by HHS.
|
Locked | Locked | Locked |
Investor details for Fina Biosolutions
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Fina Biosolutions
Investment portfolio details for Fina Biosolutions
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Fina Biosolutions
Detailed financials for Fina Biosolutions
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Fina Biosolutions Comparisons
Peer comparison for Fina Biosolutions
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Fina Biosolutions
Fina Biosolutions operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Proteros, Neovacs, Nabla, Biomatter and VERAXA, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Drug discovery services are provided to researchers in protein biochemistry.
|
|
| Locked | Locked | Locked |
Vaccine manufacturing services are provided by Neovacs CDMO.
|
|
| Locked | Locked | Locked |
Synthetic biology platform for functional protein identification is provided.
|
|
| Locked | Locked | Locked |
Provider of synthetic biology and AI-based technology for generative protein design
|
|
| Locked | Locked | Locked |
Antibody therapeutics for cancer treatment are developed via microfluidic screening.
|
Detailed competitors of Fina Biosolutions
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Fina Biosolutions
Complete news archive for Fina Biosolutions
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Fina Biosolutions
Fina Biosolutions was founded in 2006 and raised its 1st funding round 14 years after it was founded.
Fina Biosolutions is headquartered in Rockville, United States. It is registered at Rockville, Maryland, United States.
Fina Biosolutions is a funded company, having raised a total of $3M across 4 funding rounds to date.
Founded in 2006 in Rockville, United States, Fina Biosolutions operates in the biotechnology sector with a focus on bioconjugation services for vaccine discovery, development, and commercialization. Technology has been licensed to manufacturers such as GSK and Serum Institute of India. Through subsidiary Fina Reagents, proteins, polysaccharides, and antibodies related to vaccines and infectious diseases are sold. Protein purification services are also provided, alongside collaborations with drug developers.
Fina Biosolutions offers CRM 197, Functionalized Dextrans, and Conjugation Services.
Fina Biosolutions has 3 investors. Key investors include NIH, HHS, and SK bioscience.